Alain Jordan, MSc, COO
Alain has more than 15 years of experience in development and manufacturing of active implantable devices. As first employee of Endoart SA, he was playing a key role in all aspects of project and technology management. He has thorough knowledge of EU and US requirements relative to development and production of active implantable devices.
After the acquisition of Endoart SA by Allergan Inc., he was leading a multidisciplinary team of 28 people involved in development and manufacturing of active implantable devices.
André Mercanzini, PhD, Co-Founder and CTO
His doctoral thesis on the in vivo application of neurological implants formed Alevaʼs core technology. He gained product development experience at EndoArt (Allergan Medical), Sensimed SA, MIT Artificial Intelligence Lab, Zyvex Corporation (TX, USA) and Bosch Research (Silicon Valley, USA). He holds two US patents on microassembly and four patent applications in neurostimulation. André obtained his BS in Engineering Physics from the University of Toronto and PhD in Biomedical Engineering from the EPFL, Switzerland.
Alain Dransart, MSc – Clinical and Regulatory Affairs Director
He has extensive experience in medical devices, first with Haemonetics Corporation (automated blood separation), then with Medtronic Europe (pacemakers and heart valves), and most recently as a consultant in Product Management, Market Analysis and Clinical Management. He has led clinical validation of new products, market research, and product launch in Europe. Alain obtained his MS in Electrical Engineering from EPFL, and followed the PED management program at IMD, Switzerland.
BOARD OF DIRECTORS
Oern Stuge, MD, MBA, Executive Chairman
Oern Stuge MD, MBA is Chairman of Orsco Lifesciences AG.
Through this company, he holds several Executive & Non-Executive board memberships & advisory roles.
Prior to his current role at Orsco Lifesciences AG, Oern Stuge has worked 12 years for Medtronic Inc. (medical devices) in different roles incl. Senior Vice President (SVP) & President Europe & Central Asia, and SVP & President Cardiac Surgery. Oern Stuge was Member of Medtronic Executive Committee & Operating Committee.
Prior to Medtronic, he worked 6 years in senior management positions at Abbott Laboratories (diagnostics, pharmaceuticals, nutritional products & medical devices), 6 years in Medinor A/S (medical technology) in different positions incl. CEO, and 6 years as a practicing physician.
Markus Hosang, PhD
Markus Hosang is a General Partner at BioMedPartners AG in Basel. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical and diagnostics research and in many product development and marketing areas. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European investment activities. Previously, he was a Vice President at Roche in Basel, where he held several senior management positions in the Pharma R&D organization..
Dr. Hosang currently is a member of the boards of Aleva SA, Anergis SA, Okairos AG and Suppremol GmbH. Earlier he was on the boards of Omrix, Kourion, IDEA, Atugen, Avontec and Neuraxo
Juerg Eckhardt, MD
Dr. Eckhardt is an investment advisor for BB BIOTECH VENTURES. He is an experienced investor across all kinds of life science companies.
Before starting his venture capital career, he was an Associate Partner of McKinsey & Company in Zurich and New Jersey/New York, and a member of the firm’s European Healthcare Leadership team. Prior to that, Dr. Eckhardt was a resident physician at the University Hospital of Basel, Switzerland.
Dr. Eckhardt’s current or past board assignments include Anteis SA, TargeGen Inc, Cameron Health Inc., Palyon Medical Corp., Neoptics AG, and Swiss Smile Holding AG.
Martin Velasco is an entrepreneur and Business Angel with extensive experience in the IT, medical and biotech areas. He serves on the board/advisory board of several high-tech companies including: AC-Immune, Aleva, Anecova, Aridhia, Cocomore and Sumerian. Martin is also the Founder and Chairman of Infantia Foundation. He is a member of the Board of BlueOrchard, the leading private microfinance investment advisory company; Vice President of the Board of the Foundation EPFL+ and Vice Chairman of the European Tech Tour Association.
Philippe Dro, PhD, MBA
Dr. Dro brings 20 years of entrepreneurial experience in the life science industry, including a pivotal role in executing strategic transactions at several biotech and medtech companies.
Until recently, he was Chief Executive Officer and a Member of the Supervisory Board of GlycoVaxyn AG, a vaccine company that was acquired by GSK earlier this year.
Prior to this, he served as Chief Executive Officer and Chairman of the Board of Endoart S.A., a medtech company developing telemetry-driven implants for cardiac disease and obesity that was sold to Allergan, Inc.
From 1999 to 2003, he was Chief Financial Officer and Head of Business Development at drug discovery company Axovan AG, which was acquired by Actelion in November 2003. Prior to that, he held various position at Novartis, Skyepharma, and Antares Pharma.
Anthony W. Borowicz, MBA
Mr. Borowicz is Vice President Business Development of Greatbatch Inc. Greatbatch (NYSE:GB) is one of the largest medical device outsource (MDO) manufacturers in the world with $1.5bn in annual revenues serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets.
Mr. Borowicz has worked in the medical device industry for 33 years. At Greatbatch, Mr. Borowicz is responsible for mergers & acquisitions, technology licensing, venture investments and minority equity portfolio management.
Prior to Greatbatch, Mr Borowicz was VP Finance for Kendall Healthcare and Vice President & CFO for Graphics Controls.
Mr. Borowicz holds a Masters in Finance and Bachelor of Business Administration degree from Niagara University, NY.
André Mercanzini, PhD: see management
Jean-Pierre Rosat, PhD, MBA
With extensive experience in creating and developing high tech companies, Jean-Pierre has co-founded more than eight start-ups, made three trade-sales to public companies, and is well-versed in fund-raising and setting-up new projects. He has been previously CEO of Cytion SA, Apoxis SA and picoDrill SA. Jean-Pierre gained experienced with FDA and EMEA regulation while developing oncology drugs, and combines this experience with engineering ventures that focused on automated drug screening equipment and micro-machining technology.
Prof. Claudio Pollo, MD, PD&MER, FMH - Head of Functional Neurosurgery, Inselspital, Bern
Known for his innovative work in applying DBS to movement disorders, epilepsy, pain and psychiatric disorders, he has treated close to 200 patients using DBS surgery. He studied Neurosurgery under the inventor of DBS therapy, Dr. Alim Benabid in Grenoble, France. He is a co-inventor of microDBSTM technology and is Principal Investigator for Alevaʼs first-in-man studies.
Prof. Philipe Renaud, PhD, Professor EPFL
Philippe Renaud is Professor at the Microsystem Laboratory at EPFL. He is also the scientific director of the EPFL Center of MicroNanoTechnology (CMI). His main research area is related to micro and nano-technologies in biomedical applications (BioMEMS) with emphasis on cell-chips, nanofluidics and bioelectronics. Ph. Renaud is involved in many scientific papers in his research area. More than 13 successful start-ups have been created out of research conducted in his laboratory.
Paul, a co-founder of Aleva, assists the company with strategy, business development and US operations. He has been an executive at two MIT start-ups (NetBio Inc. and Boston Microsystems, recently acquired by Pall Corporation) and was a vice-president and executive officer at Ansoft Corporation (NASDAQ:ANST, acquired by ANSYS). Paul is currently CEO of Sakti Medical Systems, a U.S.-based healthcare company focused on improving outcomes for patients suffering from chronic pain and addictive disorders. He obtained his BSEE from Carnegie-Mellon and MBA from IMD.
Prof. Andres Lozano, MD, PhD
Andres is currently Professor in the Department of Surgery, and inaugural Chair Holder of the Ron Tasker Chair in Stereotactic and Functional Neurosurgery at the University Health Network. His main research and clinical interests lie in the field of the neurosurgical treatment of movement disorders and micro-electrode recordings of the human brain.
Prof. Philippe Renaud, PhD: see above
ALEVA NEUROTHERAPEUTICS SA | EPFL INNOVATION PARK - BUILDING DD | 1015 LAUSANNE | SWITZERLAND | INFO@ALEVA-NEURO.COM
|CONTACT & DIRECTIONS|